SEC Form 4 · accession 0001104659-18-049576
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven P. Gelone
Officer — President and COO
Period of report
Aug 2, 2018
Accepted (ET)
Aug 3, 2018 · 7:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF1,F2 | — | Aug 2, 2018 | A | 7,500 | A | — | Aug 2, 2028 | Ordinary Shares | 7,500 | 7,500 | D |
| Restricted Stock UnitsF3,F4 | — | Aug 2, 2018 | A | 32,000 | A | — | Jan 31, 2020 | Ordinary Shares | 32,000 | 32,000 | D |
Explanation of responses
- F1The exercise price is $2.49 per share.
- F2The option award was granted on August 2, 2018. Vesting began on July 24, 2018 and ends on July 24, 2022. Twenty-five percent (25%) of the option award will vest on July 24, 2019, and the remaining seventy-five percent (75%) of the option award will vest on a monthly pro-rata basis over the remaining vesting period.
- F3The restricted stock units shall convert into ordinary shares on a one-for-one basis upon vesting of the units.
- F4The restricted share units were granted on August 2, 2018, and are subject to vesting as follows: 50% will vest upon certification by the board of directors of the receipt of approval by the United States Food and Drug Administration (the "FDA") of a new drug application for lefamulin, and 50% will vest on the first anniversary of such certification by the board of directors, provided, in each case, that the registrant is performing services to Nabriva Therapeutics plc on the applicable vesting dates. If the FDA does not approve a new drug application for lefamulin by January 31, 2020, the restricted share units will terminate in full.